Ultragenyx Pharma (RARE) Announces Significant Data from UX007 Phase 2 in LC-FAOD
Tweet Send to a Friend
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) announced positive 78-week data from the Phase 2 study of UX007 (triheptanoin) in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
